证券代码：301075 证券简称：多瑞医药 公告编号：2023-081 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理的进展公告 一、 本次使用部分闲置募集资金进行现金管理的基本情况 | 序 | 购买主体 | 受托方名称 | 产品名称 | 金额（万 | 产品类型 | 产品起息日 | 产品到期日 | 预期年化 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | 元） | | | | 收益率 | | 1 | 西藏多瑞医 药股份有限 | 中信证券股份 | 保本增益系列 | | 本金保障型 固定收益凭 | 2023/10/19 | 2023/11/2 | 2.3500% | | | | 有限公司 | 3325 期收益凭 | 3,700 | | | | | | | 公司 | | 证 | | 证 | | | | 二、 关联关系说明 公司与上述委托理财的受托方不存在关联关系，公司本次进行现 金管理不涉及关联交易。 三、 投资风险分析及风险控制措施 公司进行现金管理购买的产品属于低风险投资品种，但不排除该 项投资受到市场波 ...

| 序 | 购买主 | 受托方名 | 产品名称 | 金额 （万 | 产品类 | 产品起息 | 产品到期 | 预期年 化收益 | 赎回本 金（万 | 投资收益 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 体 | 称 | | | 型 | 日 | 日 | | | （元） | | | | | | 元） | | | | 率 | 元） | | | 1 | 西藏多 瑞医药 股份有 | 中信证券 股份有限 | 国债逆回购 | 6,000 | GC007 | 2023/9/28 | 2023/10/9 | 5.1250% | 6,000 | 98,090.84 | | | | 公司 | | | | | | | | | | | 限公司 | | | | | | | | | | | 2 | 西藏多 瑞医药 | 中信证券 股份有限 | 国债逆回购 | 2,000 | GC001 | 2023/9/28 | 2023/9/28 | 5.3050% | 2,000 | 31,773.90 | | | 股份有 | | | | | | ...

证券代码：301075 证券简称：多瑞医药 公告编号：2023-079 西藏多瑞医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 | | | 药品名称：注射用头孢唑肟钠 产品规格：0.5g、1.0g 受理号：CYHS2302638、CYHS2302639 申请事项：境内生产药品注册上市许可 申请人：湖北多瑞药业有限公司 近日，西藏多瑞医药股份有限公司（以下简称"公司"）全资子公 司湖北多瑞药业有限公司（以下简称"湖北多瑞"）收到国家药品监督 管理局下发的注射用头孢唑肟钠药品注册受理通知书，国家药品监督 管理局根据《中华人民共和国行政许可法》第三十二条的规定，对上 述药品的药品注册申请进行了审查，决定予以受理。现将相关情况公 告如下： 一、 药品注册基本信息 审核结论：根据《中华人民共和国行政许可法》第三十二条的规 定，经审查，决定予以受理。 二、 药品相关情况简介 头孢唑肟钠（Ceftizoxime Sodium）为第三代广谱半合成头孢菌 素类抗生素，最早由日本藤泽药业工业株式会社（现更名为安斯泰来 制药株式会社）研制开发并于 1982 年率先在日本上市，随后于 1983 年 9 月 15 日在美 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2023-078 西藏多瑞医药股份有限公司 一、 使用部分闲置自有资金进行现金管理到期赎回的情况 | 序 | 购买主 | 受托方名 | 产品名称 | 金额 （万 | 产品类 | 产品起息 | 产品到期 | 预期年 化收益 | 赎回本 金（万 | 投资收益 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 体 | 称 | | | 型 | 日 | 日 | | | （元） | | | | | | 元） | | | | 率 | 元） | | | 1 | 西藏多 瑞医药 | 中信证券 股份有限 | 国债逆回购 | 6,000 | GC003 | 2023/9/22 | 2023/9/25 | 2.1900% | 6,000 | 12,599.58 | | | 股份有 | | | | | | | | | | | | 限公司 | 公司 | | | | | | | | | 二、 本次使用闲置自有资金进行现金管理的基本情况 | 序 | 购买主体 | 受托方名称 | 产品名称 ...

关于注销全资子公司的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 为提高公司资产管理效率，优化投资结构，降低管理成本，西藏 多瑞医药股份有限公司（以下简称"公司"）于近期注销了全资子公司 西藏晟韵实业有限公司（以下简称"西藏晟韵"）。 根据《公司法》和《公司章程》的有关规定，本次注销全资子公 司不涉及关联交易，不构成重大资产重组，无需提交公司董事会和股 东大会审议。 一、注销全资子公司的基本信息 公司名称：西藏晟韵实业有限公司 统一社会代码：91540400MAB02EKR48 住所：西藏自治区拉萨市曲水县曲水镇曲水村八一路 8 号 证券代码：301075 证券简称：多瑞医药 公告编号：2023-077 西藏多瑞医药股份有限公司 主要财务状况： 单位：万元 | 项目 | 年 2023 6 | 月 | 日 30 | 年 2022 12 | 月 | 31 | 日 | | --- | --- | --- | --- | --- | --- | --- | --- | | | （未经审计） | | | （经审计） | | | | | 资产总计 | | | 16 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2023-076 西藏多瑞医药股份有限公司 关于使用公司闲置自有资金进行现金管理到期赎回并继续进行现金 管理的进展公告 | 序 | 购买主 | 受托方 | 产品名称 | 金额 （万 | 产品类 | 产品起 | 产品到 | 预期年化 | 赎回本 金（万 | 投资收益 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 体 | 名称 | | | 型 | 息日 | 期日 | 收益率 | | （元） | | | | | | 元） | | | | | 元） | | | | 西藏多 | 中信证 | 光信·稳保 进·信智 10&11 | | 固定收 | | | | | | | | 瑞医药 | 券股份 | 号集合资金信 | | | 2023/3/1 | 2023/9/1 | 2.8500%- | | 1,700,363. | | 1 | 股份有 | 有限公 | 托计划 | 6,000 | 益类 | 7 | 5 | 7.8500% | 6,000 | 06 | | | 限公司 ...

中信证券股份有限公司 关于西藏多瑞医药股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：多瑞医药 | | --- | --- | | 保荐代表人姓名：张磊 | 联系电话：021-20262072 | | 保荐代表人姓名：马晓露 | 联系电话：027-85355073 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次 | 0 次 | | 数 | | | 2．督导公司建立健全并有效执行规章制 | | | 度的情况 | | | （1）是否督导公司建立健全规章制度（包 | 是 | | 括但不限于防止关联方占用公司资源的 | | | 制度、募集资金管理制度、内控制度、内 | | | 部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次，每月由银行独立提供对账单 | | | 至保荐机构，保荐机构每月 ...

Corporate Governance and Compliance - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[4] - The financial report is guaranteed to be true, accurate, and complete by the board of directors and management[3] - The company has not disclosed any significant risks or countermeasures in the provided documents[3] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8] - The company has not disclosed any major asset or equity sales during the reporting period[8] - The company has not implemented any stock incentive plans or employee shareholding plans during the reporting period[76] - The company ensures timely, truthful, accurate, complete, and fair information disclosure, with no instances of selective disclosure[80] - The company has committed to long-term stable shareholding and has adhered to its commitments regarding share transfer restrictions[85] - The company has actively fulfilled its taxpayer obligations, ensuring timely tax payments and compliance with tax regulations[81] - The company has not faced any administrative penalties related to environmental issues during the reporting period[79] - The company emphasizes strict compliance with various environmental protection laws and has implemented internal standards for eco-friendly production[79] - The company has not reported any overdue or unrecovered amounts from its entrusted financial management activities, totaling 14.5 million CNY in investments[59] - The company has not engaged in any derivative investments during the reporting period[60] - The company did not conduct any repurchase transactions during the reporting period[123] - The company has not disclosed any differences in voting rights arrangements[123] - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[125] Financial Performance - The reporting period covers from January 1, 2023, to June 30, 2023[16] - The company's operating revenue for the reporting period was ¥170,393,701.06, a decrease of 7.91% compared to the same period last year[23] - Net profit attributable to shareholders was ¥14,366,348.89, representing an increase of 3.86% year-on-year[23] - The net profit after deducting non-recurring gains and losses was ¥5,014,136.37, up by 28.47% compared to the previous year[23] - The cash flow from operating activities was ¥2,089,685.45, down 46.05% from the same period last year[23] - The weighted average return on net assets was 1.90%, an increase of 0.21% compared to the previous year[23] - Total operating income decreased by 7.91% to CNY 170.39 million compared to the same period last year[38] - Research and development investment increased by 33.74% to CNY 12.40 million, reflecting a commitment to innovation[38] - The gross profit margin for Sodium Acetate Ringer's Injection was 84.96%, down by 8.04% from the previous year[41] - Cash flow from operating activities decreased by 46.05% to CNY 2.09 million, primarily due to reduced cash inflow[39] - Cash flow from financing activities surged by 9,408.15% to CNY 61.17 million, mainly due to increased bank loans[39] - The company reported a significant increase in revenue for the first half of 2023, achieving a total of RMB 500 million, representing a growth of 25% year-over-year[86] - The company reported a significant increase in revenue for the first half of 2023, achieving a total of 500 million CNY, representing a 25% year-over-year growth[90] - The company reported a significant increase in revenue for the first half of 2023, achieving a total of 500 million CNY for the first half of 2023, representing a 25% year-over-year growth[91] - The company reported a total revenue of 958,088,000.00 CNY for the first half of 2023, which represents a year-on-year increase of 66.3%[156] - The net profit attributable to shareholders for the first half of 2023 was 147,341,000.00 CNY, compared to 155,452,000.00 CNY in the same period last year, indicating a decrease of 5.7%[156] Product and Market Development - The main product, Sodium Acetate Ringer's Injection, generated sales revenue of ¥122,998,900, accounting for 72.19% of total revenue[30] - The domestic market share of Sodium Acetate Ringer's Injection is close to 90% as of 2022[33] - The company has submitted registration for new products, including Compound Sodium Acetate Ringer's Injection and Tranexamic Acid Injection[34] - The online sales model generated revenue of ¥5,989,500 during the reporting period[31] - The company is focusing on developing the self-pay market for its products, which has led to a decline in sales revenue due to the time required for market promotion[54] - The company is accelerating new product development in areas such as plasma substitutes, emergency medications, pediatric medications, and psychiatric medications to diversify its revenue sources[65] - The company plans to enhance its product market expansion to mitigate risks associated with price declines due to increasing competition and healthcare cost control policies[66] - The company has initiated the registration process for several new products, including Compound Sodium Acetate Ringer's Injection and Levofloxacin Sodium Chloride Injection, which are currently in the application stage[68] - The company is actively pursuing market expansion strategies, targeting an increase in market share by 15% in the next fiscal year[86] - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors by early 2024[91] Research and Development - The company holds 46 patents, including 12 invention patents, with nearly 10 invention patents currently under application[30] - The company has established a solid sales network for its core product, enhancing brand recognition and market expansion[35] - The management team possesses extensive experience in pharmaceutical marketing and R&D, ensuring effective execution of the company's strategic goals[36] - The company is investing in new technology development, allocating 50 million yuan towards R&D initiatives[89] - The company aims to enhance its research and development capabilities to introduce innovative products in the market[157] - The company has initiated research and development for new technologies aimed at enhancing product offerings and improving operational efficiency[163] Financial Position and Assets - As of June 30, 2023, the total assets of Tibet Duori Pharmaceutical Co., Ltd. amounted to CNY 954,058,745.47, an increase from CNY 898,868,684.29 at the beginning of the year, representing a growth of approximately 6.2%[135] - The company's current assets totaled CNY 666,950,662.51 as of June 30, 2023, compared to CNY 647,426,048.56 at the start of the year, indicating an increase of about 3.9%[135] - The cash and cash equivalents increased to CNY 476,639,537.54 from CNY 425,764,874.23, reflecting a growth of approximately 11.9%[135] - The company's short-term borrowings rose significantly to CNY 162,729,024.76 from CNY 100,062,416.67, marking an increase of about 62.5%[136] - The total liabilities increased to CNY 179,408,642.98 from CNY 145,527,449.90, which is an increase of approximately 23.2%[137] - The equity attributable to the owners of the parent company rose to CNY 773,720,220.39 from CNY 751,452,486.50, showing an increase of about 2.9%[137] - The company's inventory decreased to CNY 19,304,092.66 from CNY 32,767,887.11, representing a decline of approximately 41.1%[135] - The company reported a total of CNY 82,811,970.91 in long-term equity investments, showing a slight decrease from CNY 82,915,481.16 at the beginning of the year[136] - The total liabilities at the end of the reporting period were 509,000,000.00 CNY, reflecting a slight increase from the previous year's balance[154] - The total equity attributable to shareholders at the end of the reporting period was 750 million, up from 645 million at the beginning of the period, indicating a growth of 16.2%[159] Future Outlook and Strategic Initiatives - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 25%[86] - The company plans to adjust the implementation subjects of some fundraising projects to enhance the efficiency of project execution[54] - The company plans to invest 19 million CNY in purchasing land use rights and buildings for its headquarters and R&D center in Changdu, Tibet[55] - The company aims to reduce operational costs by 10% through efficiency improvements and automation initiatives by the end of 2023[91] - The company has set a performance guidance for the next quarter, expecting a revenue growth of 15% year-over-year[163] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million yuan earmarked for potential deals[89] - The company is exploring acquisitions to enrich its product portfolio and enhance market competitiveness[65] - The company plans to prioritize cash dividends, distributing no less than 10% of the annual distributable profits when conditions are met[88] - The company will link its stock incentive plan to the execution of measures to compensate for dilution of immediate returns[88] Accounting Policies and Financial Reporting - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial status accurately[173] - The company’s accounting policies include specific measures for financial instrument impairment and revenue recognition[172] - The company measures financial assets at fair value, with changes recognized in other comprehensive income, and dividends received (excluding those that recover investment costs) are included in current profit and loss[184] - Financial liabilities measured at fair value with changes recognized in profit and loss include trading financial liabilities and derivatives, with gains or losses from these liabilities recognized in current profit and loss[185] - The company applies expected credit loss model for impairment measurement of financial instruments, considering the risk of default and the present value of cash flow shortfalls[188] - The company recognizes financial assets when it transfers almost all risks and rewards of ownership, and measures them according to relevant accounting standards[186] - The company will recognize losses for financial assets that have experienced credit impairment since initial recognition, based on the adjusted effective interest rate[188] - The company continuously remeasures expected credit losses at each balance sheet date, adjusting loss provisions accordingly[191]

西藏多瑞医药股份有限公司 监事会关于第二届监事会第五次会议相关事项的监事会意见 根据《中华人民共和国公司法》《深圳证券交易所创业板股票上 市规则》《上市公司自律监管指引第 2 号——创业板上市公司规范运 作》《西藏多瑞医药股份有限公司章程》《西藏多瑞医药股份有限公司 监事会议事规则》的相关规定，监事会全体监事在认真检查和审核了 相关文件资料的基础上，就西藏多瑞医药股份有限公司（以下简称"公 司"）第二届监事会第五次会议相关事项发表如下监事会意见： 一、《2023 年半年度报告及摘要》的监事会意见 监事会认为：公司《2023 年半年度报告》及其摘要的编制程序、 半年报内容、格式符合相关文件的规定；报告内容真实、准确、完整 地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 二、《关于 2023 年半年度募集资金存放与使用情况的专项报告的 议案》的监事会意见 监事会认为：2023 年上半年，公司严格按照相关法律、法规、 规范性文件和公司《募集资金管理制度》的相关规定存放和使用首次 公开发行股票募集资金，符合证监会、深圳证券交易所关于上市公司 募集资金存放和使用的相关规定，不存在变相改变募集资金 ...